

Fly-SMALS: Common RNA-dependent pathways for motor neuron degeneration in spinal muscular atrophy and amyotrophic lateral sclerosis

<https://neurodegenerationresearch.eu/survey/fly-smals-common-rna-dependent-pathways-for-motor-neuron-degeneration-in-spinal-muscular-atrophy-and-amyotrophic-lateral-sclerosis/>

Principal Investigators

J.B Schulz, A.Voigt, F.Besse, M.Gama-Carvalho, J.De Las Rivas, J.Weis

Institution

Multiple

Contact information of lead PI

Country

Germany|France|Portugal|Spain

Title of project or programme

Fly-SMALS: Common RNA-dependent pathways for motor neuron degeneration in spinal muscular atrophy and amyotrophic lateral sclerosis

Source of funding information

JPND-Cross Disease

Total sum awarded (Euro)

€ 762,991

Start date of award

01/05/2015

Total duration of award in years

3.0

The project/programme is most relevant to:

Motor neurone diseases|Spinal muscular atrophy (SMA)

Keywords

Research Abstract

Amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are characterized by degeneration of motor neurons. Both diseases are characterized by non-functional ribonucleic acid (RNA)/protein complexes and impaired neuronal RNA homeostasis, which might however be triggered by distinct mutations in the three conserved RNA- associated proteins TDP-43, FUS and SMN, respectively.

We will test the hypothesis that neurodegeneration in ALS and SMA share common molecular pathways triggered by distinct mutations through a combination of genetic, biochemical and functional studies using transcriptomic/ proteomic and computational approaches. First we will assess which genes and splicing isoforms differ in ALS compared to SMA using drosophila fly models. We seek to determine the neuronal-specific RNA-protein and protein-protein interactions established by the drosophila homologues of the disease-causing proteins Fus, TDP-43 and SMN. We thereby aim to identify common neuronal gene networks or pathways and their contribution to disease progression.

The findings will be translated to the human situation by verifying if the identified candidate genes are also mis- regulated in tissue derived from affected patients, with the goal of developing clinically relevant markers and therapeutic targets. This shall allow for reliable monitoring of ALS and SMA disease progression and the eventual development of biomarkers for early therapeutic intervention

Lay Summary

Further information available at:

Types:

Investments > €500k, JPND Projects

Member States:

France, Germany, JPND, Portugal, Spain

Diseases:

Motor neurone diseases, Spinal muscular atrophy (SMA)

Years:

2016

Database Categories:

N/A

Database Tags:

N/A